Medical affairs occupies a unique space in pharmaceutical organizations: it sits between science and commerce, maintaining scientific credibility while advancing organizational goals. The medical affairs function manages key opinion leader relationships, drives scientific exchange, oversees publication strategy, and supports the safe, effective use of the company’s medicines.
For pharma CEOs, medical affairs is a function that benefits from clear delegation while requiring CEO alignment on scientific and reputational standards.
The CEO’s Medical Affairs Role
The pharma CEO’s medical affairs involvement should focus on:
Scientific positioning strategy. The CEO ensures that the organization’s scientific strategy aligns with medical affairs activities. When the company is positioning for leadership in a particular therapeutic area, the CEO validates that medical affairs investments support that positioning.
External scientific credibility. The CEO’s own public communications, scientific presentations, and media engagement around the company’s science must be consistent with medical affairs scientific standards.
KOL relationships at the C-suite level. For the company’s most prominent scientific partners, national advisory board chairs, or scientific thought leaders who interact at an executive level, the CEO maintains direct relationships.
Medical affairs investment decisions. Staffing the MSL organization, funding congress presence, and investing in medical education programs are budget decisions that require CEO approval at the strategic level.
Cross-functional alignment. The CEO ensures that medical affairs, commercial, and regulatory functions work collaboratively rather than in silos.
Medical Affairs Delegation Framework
To the Chief Medical Officer
Medical affairs strategy leadership. The CMO owns the overall medical affairs strategy: scientific platform priorities, KOL engagement strategy, publication planning, and scientific communication strategy.
MSL organization leadership. The CMO oversees the medical science liaison organization through the VP of Medical Affairs or Head of MSLs, setting engagement standards and ensuring scientific quality.
Medical information oversight. The medical information function, which responds to healthcare professional and patient inquiries about the company’s products, is a CMO responsibility.
REMS program management. When products have Risk Evaluation and Mitigation Strategies requirements, the CMO ensures appropriate program management.
Clinical evidence generation oversight. Investigator-sponsored trials, real-world evidence studies, and post-approval research are managed through medical affairs under CMO oversight.
To the VP of Medical Affairs or Head of Medical Affairs
KOL identification and tiering. Identifying, tiering, and maintaining the KOL database is a medical affairs operations function.
MSL deployment and management. Field deployment of medical science liaisons, territory assignments, and MSL performance management belong with the head of field medical.
Advisory board management. Organizing advisory boards, recruiting participants, managing meeting logistics, and producing advisory board outputs are medical affairs operations.
Publication planning. Managing the publication plan, coordinating with data analysis teams, engaging publication agencies, and managing author relationships are publication management functions.
Congress planning. Identifying key medical congresses, planning organizational presence, coordinating scientific presentations, and managing data disclosure are medical affairs responsibilities.
To the Medical Information Function
HCP inquiry response. Responding to healthcare professional questions about product safety, efficacy, and appropriate use is a medical information function.
Unsolicited off-label request management. Managing responses to unsolicited requests for information about unapproved uses, in compliance with regulatory requirements, is a medical information and legal function.
Building Medical Affairs Delegation Infrastructure
Scientific Platform and Message Architecture
A documented scientific platform for each product or therapeutic area, developed by medical affairs in coordination with clinical, regulatory, and commercial, gives the MSL team and medical affairs operations consistent, compliant scientific messaging without requiring CEO review of each communication.
MSL Performance Metrics Dashboard
A monthly MSL performance report covering KOL interactions, scientific exchange quality, HCP reach, and field medical activities gives the CEO visibility into field medical effectiveness without operational involvement.
Publication Plan Review
A quarterly publication plan review ensures the CEO understands the organization’s scientific communication pipeline, including upcoming presentations and publications that may have commercial or reputational implications.
Advisory Board Governance
Advisory board governance policies should ensure that scientific input is genuinely sought and appropriately integrated into development decisions, not simply used for commercial purposes. The CMO owns advisory board governance; the CEO endorses the governance policy.
Pharma CEOs coordinating medical affairs with clinical and commercial operations can find complementary frameworks in delegation guide for pharma CEO: clinical operations.
The role of a chief of staff in coordinating across medical affairs, commercial, and regulatory in a pharma organization is addressed in what pharmaceutical biotech CEOs delegate to their chief of staff.
The Compliance Dimension of Medical Affairs Delegation
Medical affairs delegation requires careful attention to compliance boundaries. MSLs and medical affairs professionals operate under strict rules around promotional versus scientific communications. The CEO must ensure that the compliance infrastructure for medical affairs is adequately resourced and that the medical affairs function operates genuinely independently from commercial pressures.
This is a CEO cultural responsibility that cannot be fully delegated: modeling and enforcing the norm that scientific integrity is non-negotiable.
Conclusion
Medical affairs is a high-value function that benefits from capable, independent scientific leadership and clear operational delegation. The pharma CEO who invests in strong CMO leadership, establishes appropriate governance structures, and maintains strategic engagement with scientific positioning will build a medical affairs function that enhances the organization’s scientific credibility and clinical relationships.
Delegate the operations. Lead the culture. Trust the science.
For pharmaceutical medical affairs strategy and KOL management insights, see McKinsey.com/industries/life-sciences.
Related Reading
For further context, explore Delegation Framework for the 3PL Provider CEO and Delegation Framework for Academic Medical Center CEO.